Based in San Diego, California, Ignyta is a scientifically-driven biotechnology company that's focused on personalized medicine for autoimmune diseases. Their goal is to improve the quality of biomarkers and tests available to rheumatologists and patients, allowing for more individualized treatment decisions. They also aim to identify new autoimmune disease targets for biopharmaceutical companies to develop precise therapies for patients worldwide. In addition to their work in autoimmune diseases, Ignyta is also an oncology biotech company that's researching tumor reduction and cancer treatment through integrated therapeutic and companion diagnostics. Their portfolio includes compounds to treat adult and pediatric patients with solid tumors, as well as patients with superficial and nodular basal cell carcinoma.